

Name Marry Van den Heuvel-Eibrink

Institution Princess Máxima Center for Pediatric Oncology

Address Heidelberglaan 25
Utrecht, Utrecht, 3584 CS
Netherlands

Email Address m.m.vandenheuvel-eibrink@prinsesmaximacentrum.nl

Project Requirements and Description

Requirements to submit AOI

Requirements to submit AOI (all answers must be "yes" to proceed)

A comprehensive review of previously published data has been completed	Yes
The specific aims are clear and focused	Yes
The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator.	Yes
The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months	Yes

Project Title Genome-wide Association Studies – Ototoxicity in Patients and Survivors of Childhood Cancer

Planned research population (eligibility criteria)

The proposal consists of multiple endpoints, e.g., tinnitus and hearing loss. For both endpoint we aim to both do a nuclear and mitochondrial GWAS.

Tinnitus:

- were diagnosed with cancer before the age of 18.
- Answered a tinnitus question in CCSS follow-up surveys.
- Informed consent has been signed

Hearing loss:

- Diagnosed with cancer before the age of 19 years
- Initially treated with cisplatin, as a single platinum drug during childhood cancer treatment, or switched from cisplatin to carboplatin during treatment
- Did not receive cranial or inner ear radiation
- Have bilateral hearing dysfunction or no hearing loss as a result of platinum treatment
- Completed their chemotherapy treatment
- Have normal hearing at baseline and at least one pure tone audiometric evaluation available within two years after completion of chemotherapy

Proposed specific aims

- Project A: Identification of nuclear variants associated with CIHL in childhood cancer survivors. (joint discovery)
- Project B: Identification of mitochondrial variants associated with CIHL in childhood cancer survivors. (joint discovery)
- Project C: Identification of nuclear variants associated with tinnitus in childhood cancer survivors. (joint discovery)
- Project D: Identification of mitochondrial variants associated with tinnitus in childhood cancer survivors. (joint discovery)

Will the project require non-CCSS funding to complete?

No

If yes, what would be the anticipated source(s) and timeline(s) for securing funding?

Does this project require contact of CCSS study subjects for:

Additional self-reported information	No
Biological samples	No
Medical record data	No

If yes to any of the above, please briefly describe.

What CCSS Working Group(s) would likely be involved? (Select all that apply)

	Primary	Secondary
Second Malignancy		
Chronic Disease		✓
Psychology/Neuropsychology		
Genetics	✓	
Cancer Control		
Epidemiology/Biostatistics		✓

Outcomes or Correlative Factors

	Primary	Secondary	Correlative Factors
Late Mortality			
Second Malignancy			

Health Behaviors

	Primary	Secondary	Correlative Factors
Tobacco			
Alcohol			
Physical Activity			
Medical Screening			
Other			

If other, please specify

Psychosocial

	Primary	Secondary	Correlative Factors
Insurance			
Marriage			
Education			
Employment			
Other			

If other, please specify

Medical Conditions

	Primary	Secondary	Correlative Factors
Hearing/Vision/Speech			
Hormonal Systems			
Heart and Vascular			
Respiratory			
Digestive			

	Primary	Secondary	Correlative Factors
Surgical Procedures			
Brain and Nervous System			
Other			

If other, please specify

Medications

Describe medications

Psychologic/Quality of Life

	Primary	Secondary	Correlative Factors
BSI-18			
SF-36			
CCSS-NCQ			
PTS			
PTG			
Other			

If other, please specify

Other

	Primary	Secondary	Correlative Factors
Pregnancy and Offspring			
Family History			
Chronic Conditions (CTCAE v3)			
Health Status			

Demographic

	Primary	Secondary	Correlative Factors
Age	✓		

	Primary	Secondary	Correlative Factors
Race			
Sex	✓		
Other			

If other, please specify

Cancer Treatment

	Correlative Factors
Chemotherapy	✓
Radiation Therapy	✓
Surgery	✓

Anticipated Sources of Statistical Support

CCSS Statistical Center	No
Local Institutional Statistician	No

If local, please provide the name(s) and contact information of the statistician(s) to be involved.

Will this project utilize CCSS biologic samples?

No

If yes, which of the following?

If other, please explain

Other General Comments

We propose a collaboration on ototoxicity GWAS projects mentioned above in childhood cancer patients and survivors of the PCL cohort and DCCSS LATER cohort with the CCSS, in addition to the already established collaboration with the St. Jude Lifetime cohort study. The proposal has previously been approved by the CCSP working group at St. Jude Children's Research Hospital.

Agree

I agree to share this information with St. Jude

This Service is governed by and operated in accordance with US law. If you are located outside of the US, you use this Service voluntarily and at your own risk. If you choose to submit personal data like your name and email address, please note that your Information will be transferred to and processed in the United States. By checking this box while using this Service, you acknowledge that the data protection and other laws of other countries, such as the United States, may provide a less comprehensive or protective standard of protection than those in your country, and consent to your Information being collected, processed and transferred as set forth in the Privacy Policy and US law.